Market Place
Sourcing Support
After M&A rumors, Bausch + Lomb confirms it`s exploring a sale
12 Dec 2024 //
FIERCE PHARMA
Bausch + Lomb Acquires Elios Vision to Enhance Glaucoma Treatment
11 Dec 2024 //
BUSINESSWIRE
Bausch + Lomb Announces Third-Quarter 2024 Results
30 Oct 2024 //
BUSINESSWIRE
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Lens
14 Oct 2024 //
BUSINESSWIRE
Bausch + Lomb To Release Q3 2024 Results October 30
09 Oct 2024 //
BUSINESSWIRE
Bausch + Lomb taps broadcaster Erin Andrews for dry eye campaign
08 Oct 2024 //
FIERCE PHARMA
Bausch + Lomb Launches Opal™ Digital Marketplace In US
01 Oct 2024 //
BUSINESSWIRE
Bausch + Lomb Announces Second-Quarter 2024 Results
31 Jul 2024 //
BUSINESSWIRE
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
11 Jul 2024 //
BUSINESSWIRE
Bausch + Lomb To Present New Data At European Dry Eye Society 2024 Congress
17 Jun 2024 //
BUSINESSWIRE
Bausch+Lomb Launches Blink NutriTears Dry Eye Supplement In US
03 Jun 2024 //
BUSINESSWIRE
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
29 May 2024 //
BUSINESSWIRE
Bausch+Lomb: New Data On Consumer, Vision, Pharma Products At Optometry Meet
28 May 2024 //
BUSINESSWIRE
Bausch + Lomb Announces First-Quarter 2024 Results
01 May 2024 //
BUSINESSWIRE
Bausch + Lomb New Data at ARVO 2024
29 Apr 2024 //
BUSINESSWIRE
Bausch + Lomb: Dry Eye Nutritional Supplement Study Shows Positive Results
25 Apr 2024 //
BUSINESSWIRE
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results
21 Feb 2024 //
BUSINESSWIRE
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results
05 Feb 2024 //
BUSINESSWIRE
Bausch + Lomb puts new spin on annual glaucoma campaign with a focus on ‘Faces’
03 Jan 2024 //
ENDPTS
Bausch + Lomb Announces Third-Quarter 2023 Results
01 Nov 2023 //
BUSINESSWIRE
Bausch + Lomb Will Present New Scientific Data at Annual Meeting
26 Oct 2023 //
BUSINESSWIRE
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
16 Oct 2023 //
BUSINESSWIRE
Bausch + Lomb Will Present New Scientific Data and Analyses
04 Oct 2023 //
BUSINESSWIRE
Bausch + Lomb Completes Acquisition of XIIDRA®
29 Sep 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
14 Sep 2023 //
BUSINESSWIRE
Bausch + Lomb Launches MIEBO in the United States
12 Sep 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA
11 Sep 2023 //
ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
11 Sep 2023 //
BUSINESSWIRE
Bausch`s Bausch + Lomb Announces Disclosure of Historical Financial Information
06 Sep 2023 //
ACCESSWIRE
Bausch + Lomb Will Present New Scientific Data on its Surgical Products
06 Sep 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Disclosure of Pro Forma Financial Information
06 Sep 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA
24 Aug 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Second-Quarter 2023 Results
02 Aug 2023 //
BUSINESSWIRE
Bausch + Lomb Solidifies Leadership Team
01 Aug 2023 //
BUSINESSWIRE
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
11 Jul 2023 //
BUSINESSWIRE
Bausch + Lomb expands eye-care portfolio with J&J`s Blink
07 Jul 2023 //
REUTERS
Bausch + Lomb buys Novartis drugs for $1.75 billion to boost eye-care portfolio
01 Jul 2023 //
REUTERS
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10
12 Jun 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Scientific Data and Analyses Featuring Consumer Products
08 Jun 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq win approval for dry eye disease treatment
19 May 2023 //
ENDPTS
Bausch + Lomb Appoints Bob Bailey as Executive VP & Andrew Stewart as President
12 Apr 2023 //
BUSINESSWIRE
Bausch + Lomb & Novaliq Announce Publication of Phase 3 Data on NOV03
22 Mar 2023 //
BUSINESSWIRE
Brent Saunders to return as Bausch + Lomb CEO
16 Feb 2023 //
REUTERS
Bausch + Lomb asks macular degeneration patients to share the sights
10 Feb 2023 //
ENDPTS
Bausch + Lomb buys cataract lens maker AcuFocus
20 Jan 2023 //
FIERCE BIOTECH
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels
09 Jan 2023 //
BUSINESSWIRE
Bausch + Lomb Publishes Presentation for J.P. Morgan Healthcare Conference
09 Jan 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03
04 Jan 2023 //
BUSINESSWIRE
Bausch + Lomb Announces Third-Quarter 2022 Results
02 Nov 2022 //
PRNEWSWIRE
Bausch + Lomb & Novaliq Announce USFDA Filing Acceptance for Investig. NOV03
06 Sep 2022 //
PRNEWSWIRE
Bausch + Lomb Announces Second-Quarter 2022 Results
04 Aug 2022 //
PRNEWSWIRE
Bausch + Lomb, Sanoculis Sign Strategic Agreements for Unmet Needs in Glaucoma
28 Jul 2022 //
PRNEWSWIRE
Bausch + Lomb and Novaliq Submit NDA for Investigational Treatment NOV03
07 Jul 2022 //
PRNEWSWIRE
Bausch + Lomb Announces Scientific Data on XIPERE to be Presented During ASRS
06 Jul 2022 //
PRNEWSWIRE
Bausch + Lomb, Nicox Sue Gland Pharma to Block Generic Eye Drops
01 Jul 2022 //
BLOOMBERG LAW
Bausch + Lomb Announces Scientific Data on Latest Biotrue Products
06 Jun 2022 //
PRNEWSWIRE
New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness
02 Jun 2022 //
PRNEWSWIRE
Bausch + Lomb Corporation Files Financial Statements for First Quarter of 2022
16 May 2022 //
PRNEWSWIRE
New Survey Shows Retina Specialists Believe Suprachoroidal Administration
12 May 2022 //
PRNEWSWIRE
Bausch Health And Bausch + Lomb Announce Closing Of IPO
10 May 2022 //
BAUSCHHEALTH
